All In Biotech

Drug Trial Radar · NCT05476783

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

A Multi-center Open-label Long Term Extension Study to Assess the Safety of TB006 in Patients Who Have Completed Protocol TB006AD2102 and in De Novo Patients With Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

119

Actual

Start

Sep 15, 2022

Primary completion

Nov 17, 2023

Study completion Nov 17, 2023

Sponsor

Lead sponsor
TrueBinding, Inc.Industry
Sponsor type
Industry
First posted
Jul 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.

Conditions

  • Alzheimer's Disease

Interventions

  • TB006Drug

    Clear to slightly opalescent, sterile solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events and Serious Adverse EventsTime frame: Up to 61 weeks
  2. Number of Participants With Clinically Significant Clinical Laboratory Parameter ValuesTime frame: Up to 61 weeks
  3. Number of Participants With Clinically Significant Vital Sign ValuesTime frame: Up to 61 weeks
  4. Number of Participants With Clinically Significant 12-Lead Electrocardiogram FindingsTime frame: Up to 61 weeks
  5. Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline and up to 61 weeks
  6. Plasma Concentration of TB006Time frame: Pre-dose, and Weeks 1, 5, 9, 13, 17, 21, 25, 45, 73, 101, 113 and ED/EOS up to Week 61
  7. Number of Participants With Anti-TB006 AntibodiesTime frame: Up to 61 weeks

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    San Diego, California

  • Clinical Trial Site

    Delray Beach, Florida

  • Clinical Trial Site

    Lady Lake, Florida

  • Clinical Trial Site

    Maitland, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    Miami, Florida

  • Clinical Trial Site

    West Palm Beach, Florida

  • Clinical Trial Site

    Winter Park, Florida

  • Clinical Trial Site

    Winter Park, Florida

  • Clinical Trial Site

    Decatur, Georgia

  • Clinical Trial Site

    Matthews, North Carolina

  • Clinical Trial Site

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.